Tags: 
The COVID19 has taken the world by a stranglehold and the outbreak is causing significant disruptions in clinical research which is facing significant challenges.
The process for conducting conventional clinical trials become difficult and risky at a time when the public is advised to shelter at home and healthcare facilities become overwhelmed with caring for seriously ill patients.
With the Global Pandemic in full effect, uncertainties around rare disease clinical trials are abundantly obvious. Addressing the most appropriate response during these unpredictable months ahead is to build fact-based scenario plans.
It is critical to engage, now, with solutions sensitive enough to reflect the rapidly changed opportunities.
These activities will guarantee a speedy take off as soon as the Global Pandemic will be over.
BBCR’s solutions for your consideration:
- Reevaluate pipeline to optimize timeline and resources
- Streamline clinical plan striving for cost-efficiency
- Assess complexity of study protocol to minimize challenges
- Explore innovative regulatory strategies for pIND/IND
- Implement RWE approach to speed up trial enrolment
Act now, together we will manage COVID19 Global Pandemic disruption in RARE DISEASE clinical research
Contact us: [email protected]/bbcr2
Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.